One of the big challenges with oncology at the moment is the sheer proliferation of pathways, targets and opportunities as this slide about IGF-1R and related pathways from Dr Andrew Godwin at Fox Chase Cancer Center at the ASCO 2008 meeting shows:


There are, of course, many other pathways and possible kinase targets.  Nobody really knows which ones will be useful or critical in which tumours, however, so the whole process of R&D becomes a crapshoot.

Which means that when business development and licensing departments meet with their clinical and marketing counterparts to discuss opportunities, this is inevitably the situation that arises:

Picture 2

Reblog this post [with Zemanta]